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Summary Twenty patients with hypercalcaemia due to malignancy, which persisted following rehydration,
were treated with the bisphosphonate, aminohexane bisphosphonate (AHBP), which is structurally similar to
pamidronate. The treatment given was a single infusion of 125 mg of AHBP in 500 ml of normal saline infused
over 4 h. Serum and urine biochemistry were measured before and after treatment. Acute toxicity was
evaluated with particular attention to gastrointestinal symptoms, acute-phase reaction and change in renal
function, as judged by serum creatinine. The infusion of AHBP induced a rapid fall apparent by day 3
(P<0.001), with a nadir at day 7. The serum calcium remained lower at days 14 and 28 than at day 0, but the
numbers followed up were low (n = 5 and n = 4). In all 20 patients there was a fall in serum calcium after
treatment, and in 13 (65%) normocalcaemia was achieved. Failure to respond completely to AHBP appeared
to be associated with a renal mechanism of hypercalcaemia. Treatment was associated with a significant
decrease in fasting urinary calcium excretion (P<0.05). There was no change in white cell count or renal
function following AHBP and only two cases of mild pyrexia after infusion. We conclude that aminohexane
bisphosphonate is an effective agent in the treatment of tumour-induced hypercalcaemia, with rapid onset of
effect and low toxicity.
Hypercalcaemia is a common complication of malignancy,
occurring both in patients with solid tumours, particularly
carcinoma of the breast and bronchus, and in patients with
haematological malignancy. The pathophysiology of the con-
dition varies according to the primary tumour and the
presence or absence of focal bone metastases, but in the
majority of cases the predominant mechanism is one of
increased bone resorption (Bonjour & Rizzoli, 1989). Treat-
ment strategies have therefore focused on the inhibition of
bone resorption, and over the past decade the bisphos-
phonates, specific and potent inhibitors of osteoclast-
mediated bone resorption, have become the treatment of
choice (Coleman & Rubens, 1987; Urwin et al., 1987; Kanis
et al., 1991).
The bisphosphonates have in common the central P-C-P
structure, but modifications of the side chains alter their
biological characteristics, particularly their potency. There are
currently three bisphosphonates available for the treatment
of tumour-induced hypercalcaemia: 1-hydroxyethylidene-1,1-
bisphosphonic acid (HEBP or etidronate), dichloromethylene-
bisphosphonic acid (Cl2MBP or clodronate) and 3-amino-i-
hydroxypropylidene-l ,1-bisphosphonic acid (AHPrBP or
pamidronate). Pamidronate is the most potent, and research
on other experimental compounds suggests that the amino
derivatives are particularly active (Shinoda et al., 1983; Riz-
zoli et al., 1992).
However, clinical studies have shown that pamidronate
may be associated with a transient acute-phase response
which can be manifested as pyrexia or leucopenia (Gallacher
et al., 1989; Morton et al., 1989). In addition, there are
reports of muscle rigors, general malaise, thrombophlebitis
and hypocalcaemia, and with the oral formulation gastro-
intestinal side-effects are not uncommon (van Holten-
Verzantvoort et al., 1987).
In this pilot study we have examined the effect of 6-amino,
1-hydroxyhexylidene-l,l-bisphosphonic acid (AHBP) on
tumour-induced hypercalcaemia. This agent is structurally
very similar to pamidronate. The aim was to assess the acute
effects of a single infusion in the treatment of hypercalcaemia
due to malignancy.
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Patients and methods
Twenty patients (10 men, 10 women) with tumour-induced
hypercalcaemia received treatment with aminohexane bis-
phosphonate (neridronate). The mean age of the patients was
61.3 years (range 32-82 years). The primary tumours involved
were four breast, four bronchus, three renal cell carcinoma,
two bladder, one myeloma, one rectum, one non-Hodgkin's
lymphoma, one cervix, one parotid, one nasopharynx and
one adenocarcinoma of unknown primary. Of the 20 patients,
ten had bone metastases demonstrated on radiography and/
or skeletal scintigraphy (not including the patient with
myeloma).
Patients were selected for treatment if hypercalcaemia
(adjusted serum calcium >2.63 mmol 1-) persisted following
48 h of extracellular volume expansion with 61 of physio-
logical saline. Treatment was administered as a single intra-
venous infusion of 125 mg of AHBP in 500 ml of saline given
over 4 h. Saline infusion was then continued until serum
calcium fell to within the normal range.
Venous blood samples were taken at time of diagnosis of
hypercalcaemia (day -2), on the day of treatment (day 0),
and at days 3, 5 and 7 and, where possible, at days 14 and
28. Full blood count was measured on each of these
occasions, and serum calcium, albumin, creatinine and
alkaline phosphatase were measured by Technicon SMAC.
Total serum calcium values were adjusted for fluctuations in
albumin concentration. A 2 h fasting urine sample was taken
at day 0 and at day 5 for the measurement of calcium and
creatinine. Fasting calcium excretion was expressed as a
molar ratio of creatinine excretion (upper limit of normal
0.30 mmol mmol-' creatinine), and was interpreted as a
measure of bone resorption (Kanis et al., 1980). Renal
tubular reabsorption of calcium was estimated by use of a
nomogram that plots serum calcium against calcium excre-
tion (Percival et al., 1985).
Temperature was recorded on each patient 6-hourly from
the start of infusion for 3 days. Episodes of vomiting, diarr-
hoea, nausea and malaise were recorded by the nursing staff.
Note was taken of radiotherapy or chemotherapy given
within the 2 weeks prior to treatment or within 2 weeks
following treatment.
Results are expressed as the mean ± standard error of the
mean. Paired t-tests were used to compare mean values
before and after treatment.
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Results
Treatment with a single infusion of aminohexane bisphos-
phonate induced a rapid and significant fall in adjusted
serum calcium (Figure 1). There was a reduction in serum
calcium following rehydration - 3.38 ± 0.15 mmol 1' at day
-2 fell to 3.24±0.12mmoll` at day 0 - but this was not
statistically significant. By day 3, however, the adjusted cal-
cium value fell in all patients and the mean value was
significantly lower than that at day 0 (2.91 ± 0.09 mmol 1`;
P = 0.001 on paired t-test). There were further falls at days 5
and 7 to 2.69 ± 0.09 and 2.54 ± 0.10 mmol 1-' respectively
(P<0.001 in both cases). The reduction in serum calcium
was maintained at days 14 and 28 (2.62 ± 0.24 and
2.76 ± 0.20 mmol I`), but the numbers of patients followed
up were low (n = 5 and n = 4). (Eight of the 20 patients died
within 28 days of treatment, five of whom remained hyper-
calcaemic until death and three of whom had responded to
treatment. Of the remaining patients, those who became
normocalcaemic and were well enough to be discharged were
not available for follow-up to 28 days.) In 13 of the 20
patients (65%) serum calcium was reduced to within the
laboratory reference range after treatment. There were no
cases of hypocalcaemia following treatment.
Treatment was also associated with a significant fall in
mean fasting urinary calcium excretion, which fell from
1.56 ± 0.05 mmol mmol-' creatinine at day 0 to
0.31 ± 0.08 mmol mmol-' creatinine at day 5 (P<0.05)
(Table I). This demonstrates that the dose of bisphosphonate
used was adequate to suppress bone resorption to normal
levels. In those patients in whom normocalcaemia was
induced after treatment, the mean fasting urinary calcium
before treatment was 1.66 mmol mmol' creatinine,
indicating a high net rate of bone resorption. By contrast, the
fasting urinary calcium before treatment in the patients who
did not respond completely was 0.25 mmol mmol- ' creatinine
(though samples were available in only three patients). How-
ever, there was no significant difference between initial serum
calcium in the patients who became normocalcaemic after
treatment and those who did not. Neither was there any
difference in the pretreatment serum creatinine between the
two groups.
The two major mechanisms contributing to the develop-
ment of tumour-induced hypercalcaemia are increased bone
resorption and increased renal tubular reabsorption of cal-
cium. Whereas the increased bone resorption responds to
bisphosphonate therapy, the renal effect does not. In this
group of patients the overall renal tubular reabsorption of
calcium was 2.73 ± 0.14 mmol I' prior to treatment and fell
to 2.61 ± 0.22 mmol 1` following AHBP, a non-significant
change (upper limit of normal is 2.63 mmol 1`). Those
patients who subsequently became normocalcaemic had a
mean renal tubular reabsorption of 2.63 ± 0.16 mmol 1'
before treatment, whereas the incomplete responders had
evidence of increased renal tubular reabsorption of calcium
with a pretreatment mean of 3.06 ± 0.32 mmol -'.
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Figure 1 Serum calcium (mean ± s.e.m.) in 20 patients after a
single infusion of AHBP 125 mg. **P<0.001.
Table I Indices of bone resorption (fasting urinary calcium
excretion in mmol mmol- ' creatinine) and renal tubular reabsorption
of calcium (mmol I') before and after treatment with AHBP
Urinary calcium Tubular
(mmolmmol-' reabsorption of
creatinine) calcium (mmolI-')
Responders
Baseline 1.66 0.41 2.63 0.16
Incomplete responders
Baseline 0.25 ± 0.20 3.06 ± 0.32
All patients
Baseline 1.56 0.50 2.73 0.14
After AHBP 0.31 ± 0.08 2.61 ± 0.22
Difference P <0.05 NS
NS, not significant.
There was no change in mean serum creatinine between
days 0 and 3 (136±29gtLmoll and 124±24,tmoll'I) so
that, even though there was some degree of renal impairment
initially, treatment did not cause any further deterioration in
renal function. Serum alkaline phosphatase was unaltered by
treatment. Total white cell count fell between days 0 and 3
from 10.1 ± 1.2 to 8.6± 1.1 x 1091-' (P<0.05). This was
unduly influenced by two patients who received cytotoxic
chemotherapy within 3 days prior to bisphosphonate treat-
ment. Of three patients in whom total white cell count fell
below the normal range (<4 x I09 1'), this included the two
who had received concomitant chemotherapy.
Three different patients received radiotherapy to their
primary lesion at the same time as bisphosphonate treatment.
These patients had squamous carcinoma of the lung,
squamous carcinoma of the nasopharynx and transitional cell
carcinoma of the bladder, and none of the three became
normocalcaemic in spite of both bisphosphonate and
radiotherapy. Excluding the five patients who received these
concomitant therapies 73% (11/15) of patients became nor-
mocalcaemic after treatment with AHBP.
Two patients (10%) experienced pyrexia (37.5° and 38°C)
within 24 h of infusion, in the apparent absence of infection.
In both the temperature returned to normal by the following
day. Two patients complained of nausea within 2 days of
treatment, but this was non-specific and could not be con-
clusively attributed to the bisphosphonate. In two patients
loose bowel motions were noted on the day after infusion,
which may have been a related adverse effect. A third patient
had severe diarrhoea that lasted for 3 days, but the patient
had recurrent hypercalcaemia 6 weeks later which was re-
treated with aminohexane bisphosphonate without any
adverse effect, and it was considered that bowel symptoms
were not bisphosphonate induced.
Discussion
This preliminary investigation demonstrates the calcium-
lowering effect of aminohexane bisphosphonate in the treat-
ment of tumour-induced hypercalcaemia. In all patients
treated there was a fall in serum calcium, and 65% of
patients became normocalcaemic. As with the other bisphos-
phonates thus far tested, this calcium-lowering activity is
mediated by inhibition of bone resorption, as judged by a
significant reduction in the fasting urinary excretion of cal-
cium (Coleman & Rubens, 1988; Bonjour & Rizzoli, 1989;
O'Rourke et al., 1993).
The dose chosen for this study was taken from our
previous experience with this bisphosphonate in the treat-
ment of Paget's disease of bone. We observed significant
decreases in disease activity with intravenous treatments of
25 or 50 mg given daily for 5 days (Atkins et al., 1987). In
the only previous reported use of aminohexane in hypercal-
caemia, eight patients received 25-50mg daily for 5 days,
which resulted in a fall in mean serum calcium (Hamdy et al.,
1987; abstract, numerical results not reported). Experience
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with clodronate in the treatment of hypercalcaemia suggests
that the use of a single infusion with an equivalent total dose
to that of the 5 day treatment may be equally effective in
lowering serum calcium but is more rapid in onset of effect
and is obviously more convenient to administer (O'Rourke et
al., 1993). For this reason we decided on single-infusion
therapy and opted cautiously for the lower total dose of
125 mg. It is appropriate that future studies should investi-
gate the effects of higher and lower doses to determine
whether there is a dose-response relationship.
With the dose we used serum calcium fell to normal in
65% of the patients, although there was a fall in serum
calcium in all patients. As with the single infusion of clo-
dronate, the onset of effect was rapid with a significant
decrease in serum calcium by day 3. The nadir was at day 7
and the effect appeared to be maintained to 28 days.
Studies using pamidronate report a variable success rate of
between 66% and 90% (Ralston et al., 1988, 1989) since the
response rate varies according to the mechanism of induction
of hypercalcaemia (Thiebaud et at., 1990). Whereas increased
bone resorption is usually the major mechanism contributing
to development and maintenance of tumour-induced hyper-
calcaemia, there is a substantial minority of patients in whom
increased renal tubular reabsorption of calcium plays a
significant role, probably related to the humoral secretion of
PTHrP (Bonjour & Rizzoli, 1989). This is particularly the
case in patients with squamous cell carcinoma or transitional
cell carcinoma. In such patients, bisphosphonate therapy will
inhibit bone resorption but not renal tubular reabsorption of
calcium, and so there is only an incomplete response of
serum calcium to treatment (Thiebaud et al., 1990).
In the present study we also observed incomplete responses
to treatment which may have been due to the presence of
increased renal tubular reabsorption of calcium. Of the seven
patients who did not become normocalcaemic following
treatment, three had squamous cell carcinoma, two had tran-
sitional cell carcinoma, one had non-Hodgkin's lymphoma
and one had renal cell carcinoma. The mean renal tubular
reabsorption of calcium was elevated in these patients prior
to treatment, and only two of the seven had documented
bone metastases, which supports the suggestion that humoral
mechanisms had increased renal tubular reabsorption of cal-
cium and that this was the predominant mechanism ofhyper-
calcaemia in these patients. Moreover, the fasting urinary
calcium, an index of bone resorption, was markedly increased
before treatment in those patients who showed a complete
response, but was much lower in those who did not respond
completely. There was no difference in initial serum calcium
or creatinine between the two groups, which suggests a
predominantly renal mechanism of hypercalcaemia in the
patients who did not achieve normocalcaemia after treat-
ment. Unfortunately, complete urine results from before and
after treatment were available on only one of the non-
responders.
With regard to acute toxicity, the dose and regimen of
aminohexane bisphosphonate used in this study appeared to
be less toxic than treatment with the other amino derivative,
pamidronate. Hypocalcaemia did not occur and there were
no reported episodes of malaise. Ten per cent of patients
experienced a self-limiting mild pyrexia, with a further 10%
suffering gastrointestinal symptoms. The observed fall in
total white cell count after treatment was slight and not
significant when those patients who had received concomitant
cytotoxic chemotherapy were excluded. This compares
favourably with the toxicity profile observed with the other
amino bisphosphonates pamidronate and alendronate, both
of which are normally associated with an acute-phase re-
sponse (Mautalen et al., 1984; Adami et al., 1987).
We conclude that aminohexane bisphosphonate is an
effective treatment for tumour-induced hypercalcaemia due to
increased bone resorption, at the dose tested. It appears to
have fewer side-effects than its structural analogue pami-
dronate. Both the duration of response and the optimum
dose are not known and need to be clarified by further
investigation.
The AHBP used was kindly donated by Instituto Gentilli, Italy.
References
ADAMI, S., BHALLA, A.K., DORIZZI, R., MONTESANI, F., ROSINI, S.,
SALVAGNO, G. & LOCASCIO, V. (1987). The acute phase response
after bisphosphonate administration. Calcif. Tiss. Int., 41,
326-331.
ATKINS, R.M., YATES, A.J.P., GRAY, R.E.S., URWIN, G.H., HAMDY,
N.A.T., BENETON, M.N.C., ROSINI, S. & KANIS, J.A. (1987).
Aminohexane diphosphonate in the treatment of Paget's disease
of bone. J. Bone. Min. Res., 2, 273-279.
BONJOUR, J.P. & RIZZOLI, R. (1989). Pathophysiological aspects of
therapeutic approaches of tumoral osteolysis and hypercalcaemia.
Rec. Res. Cancer. Res., 116, 29-39.
COLEMAN, R.E. & RUBENS, R.D. (1988). 3(amino-1,1-hydroxy-
propylidene)bisphosphonate (APD) for hypercalcaemia of breast
cancer. Br. J. Cancer, 56, 621-625.
GALLACHER, S.J., RALSTON, S., PATEL, U. & BOYLE, I.T. (1989).
Side-effects of pamidronate. Lancet, i, 42-43.
HAMDY, N.A.T., GRAY, R.E.S., URWIN, G.H., MURRAY, S.A.,
ROSINI, S. & KANIS, J.A. (1987). Effects of the diphosphonate
AHDP in hypercalcaemia. In Calcium Regulation and Bone
Metabolism. Basic and Clinical Aspects, Vol. 9. Cohn, D.V.,
Martin, T.J. & Meunier, P.J. (eds), p. 710. Excerpta Medica:
Amsterdam.
KANIS, J.A., CUNDY, T., HEYNEN, G. & RUSSELL, R.G.G. (1980).
The pathophysiology of hypercalcaemia. Metab. Bone Dis. Rel.
Res., 2, 151-159.
KANIS, J.A., McCLOSKEY, E.V., O'ROURKE, N., PRESTON, E.,
GREAVES, M., EYRES, K. & VASIKARAN, S. (1991). Bisphos-
phonates in the management of hypercalcaemia ofmalignancy. In
Tumour-induced Hypercalcaemia and its Management. Russell,
R.G.G. & Kanis, J.A. (eds). Royal Society of Medicine: London.
MAUTALEN, C.A., CASCO, C.A., GONZALEZ, D., GHIRINGHELLI,
G.R., MASSIRONI, C., FROMM, G.A. & PLANTALECH, L. (1984).
Side effects of disodium aminohydroxypropylidene-
diphosphonate (APD) during treatment of bone diseases. Br.
Med. J., 288, 828-829.
MORTON, A., DODWELL, D.J. & HOWELL, A. (1989). Disodium
pamidronate for the management of hypercalcaemia of malig-
nancy: comparative studies of single dose versus daily infusions
and of infusion duration. In Disodium Pamidronate in the Treat-
ment of Malignancy-related Disorders, Burckhardt (ed.), pp. 85-
100. Hans Huber: Berne.
O'ROURKE, N.P., McCLOSKEY, E.V., VASIKARAN, S., EYRES, K.,
FERN, D. & KANIS, J.A. (1993). Effective treatment of malignant
hypercalcaemia with a single infusion of clodronate. Br. J.
Cancer, 67, 560-563.
PERCIVAL, R.C., YATES, A.J.P., GRAY, R.E.S., GALLOWAY, J.,
ROGERS, K., NEAL, F.E. & KANIS, J.A. (1985). Mechanisms of
malignant hypercalcaemia in carcinoma of the breast. Br. Med.
J., 291, 776-779.
RALSTON, S.H., ALZAID, A.A., GALLACHER, S.J., GARDNER, M.D.,
COWAN, R.A. & BOYLE, I.T. (1988). Clinical experience with
aminhydroxypropylidene bisphosphonate (APD) in the manage-
ment of cancer-associated hypercalcaemia. Q. J. Med., 68,
825-834.
RALSTON, S.H., GALLACHER, S.J., PATEL, U., DRYBURGH, F.J.,
FRASER, W.D., CAVAN, R.A. & BOYLE, I.T. (1989). Comparison
of three intravenous bisphosphonates in cancer associated hyper-
calcaemia. Lancet, i, 1180-1182.AMINOHEXANE IN MALIGNANT HYPERCALCAEMIA 917
RIZZOLI, R., BUCHS, B. & BONJOUR, J.P. (1992). Effect of a single
infusion of alendronate in malignant hypercalcaemia: dose
dependency and comparison with clodronate. Int. J. Cancer, 50,
706-712.
SHINODA, H., ADAMEK, G., FELIX, R., FLEISCH, H., SCHENK, R. &
HAGAN, P. (1983). Structure-activity relationship of various bis-
phosphonates. Calcif. Tiss. Int., 35, 87-99.
THIEBAUD, D., JAEGER, P. & BURCKHARDT, P. (1990). Response to
treatment of malignant hypercalcaemia with bisphosphonate
AHPrBP (APD): respective role of kidney and bone. J. Bone
Min. Res., 5, 221-226.
URWIN, G.H., YATES, A.J.P., GRAY, R.E.S., HAMDY, N.A.T.,
McCLOSKEY, E.V., PRESTON, E. & KANIS, J.A. (1987). Treatment
of hypercalcaemia of malignancy with intravenous clodronate.
Bone, 8 (Suppl. 1), 43-51.
VAN HOLTEN-VERZANTVOORT, A.T., BIJVOET, O.L.M., CLETON,
F.J., HERMANS, J. & KROON, D.M. (1987). Reduced morbidity
from skeletal metastases in breast cancer patients during long-
term bisphosphonate (APD) treatment. Lancet, i, 983-985.